|1.||Bao, Chun-de: 3 articles (07/2009 - 01/2008)|
|2.||Tanaka, K: 3 articles (01/2007 - 04/2002)|
|3.||Aikawa, Y: 3 articles (11/2003 - 12/2001)|
|4.||Du, Fang: 2 articles (07/2009 - 01/2008)|
|5.||Fan, Wei: 2 articles (07/2009 - 01/2008)|
|6.||Dai, Min: 2 articles (07/2009 - 01/2008)|
|7.||Lü, Liang-jing: 2 articles (04/2008 - 01/2008)|
|8.||Teng, Jia-lin: 2 articles (04/2008 - 01/2008)|
|9.||Yamamoto, T: 2 articles (11/2003 - 04/2002)|
|10.||Sun, Xiaoxun: 1 article (01/2015)|
01/01/2015 - "Our results suggest that T-614 yields a strong improvement in arthritis via exact suppression of RANKL/OPG, IL-17, and MMP-3 expression in RASFs. "
01/01/2008 - "Oral T-614 inhibited paw swelling and offered significant protection against arthritis-induced cartilage and bone erosion, comparable to the effects of methotrexate. "
12/20/2002 - "T-614 (N-[3-(formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl]methanesulfonamide), a newly developed anti-rheumatic drug under clinical trial, is an anti-inflammatory agent which has been reported to show the inhibitory effect of bone destruction in vivo arthritis model. "
04/05/2008 - "T-614, a new slow-acting drug, is effective in treatment of rheumatoid arthritis and is well tolerated."
04/05/2008 - "Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial."
04/05/2008 - "A novel anti-rheumatic drug, T-614, has been shown to have an anti-inflammatory effect and to improve abnormal immunological findings in rheumatoid arthritis (RA). "
01/01/2008 - "T-614 is a novel oral antirheumatic agent for the treatment of rheumatoid arthritis. "
01/01/2005 - "[T-614 for therapy of rheumatoid arthritis]."
|3.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
|4.||Autoimmune Diseases (Autoimmune Disease)
01/01/2008 - "Our data suggested that T-614 is an effective disease-modifying agent that can prevent bone/cartilage destruction and inflammation in in CIA rats. "
01/01/2008 - "T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis."
01/01/2015 - "T-614 (also named as iguratimod), a novel antirheumatic drug, could attenuate joint inflammation and articular damage in rheumatoid arthritis (RA) patients, providing a new therapy for RA. "
11/01/1992 - "T-614, at doses more than 10 mg/kg p.o., exhibited a significant inhibitory effect on the increased levels of bradykinin released into the pouch fluid of kaolin-induced inflammation in rats. "
07/01/1992 - "In in vivo experiments, at doses of more than 1 mg/kg, T-614 reduced the PGE2 contents in inflammatory exudate of rat carrageenin-sponge type inflammation, but it was almost inactive in inhibiting gastric prostaglandins production up to 100 mg/kg. T-614 also did not affect the urinary PGE2 excretion in rats, and slightly inhibited the thromboxane synthesis in rat blood. "
|2.||Interleukin-17 (Interleukin 27)
|7.||Interleukin-6 (Interleukin 6)